Abstract
Our understanding of the molecular pathogenesis of LAMA2-related muscular dystrophy (LAMA2-MD) requires improving. Here, we report the phenotype, neuropathology and transcriptomics data (scRNA-seq and bulk RNA-seq) of a new Lama2 knockout mouse (dyH/dyH) which was created based on the human LAMA2-MD mutation hotspot region using CRISPR-Cas9. The dyH/dyH mice presented severe phenotype with muscular dystrophy. Mouse brain scRNA-seq showed that Lama2 gene was expressed predominantly and specifically in vascular and leptomeningeal fibroblasts and vascular smooth muscle cells, and weakly in astrocytes in wild-type mouse. Laminin α2 expression on the cortical surface was observed with immunofluorescence. In dyH/dyH, Lama2 expression is decreased in those cell types, which might be associated with the disruption of gliovascular basal lamina assembly. Additionally, transcriptomic investigation of muscles showed 2020 differentially expressed genes which are mainly associated with the impaired muscle cytoskeleton and development. In summary, this study provided useful information for understanding the molecular pathogenesis of LAMA2-MD.
Introduction
LAMA2-related muscular dystrophy (LAMA2-MD) is an autosomal recessive disorder caused by pathogenic variants in the LAMA2 gene (Zambon et al., 2020). The clinical features of LAMA2-MD can be divided into two subgroups: 1. severe, early-onset LAMA2-related congenital muscular dystrophy (LAMA2-CMD, OMIM 607855), and 2. mild, late-onset autosomal recessive limb-girdle muscular dystrophy-23 (LGMDR23, OMIM 618138) (Tan et al., 2021). LAMA2-MD has an estimated prevalence of 4 in 500,000 children (Nguyen et al., 2019), and accounts for 36%-48% of all patients diagnosed with congenital muscular dystrophies (CMDs) (Sframeli et al., 2017; Abdel Aleem et al., 2020; Ge et al., 2019). Muscle weakness with dystrophic muscle pathology and abnormal brain white matter hyperintensities on T2-weighted magnetic resonance imaging (MRI) are the common characteristics of LAMA2-MD patients. Some patients present brain dysfunctions such as seizures and cognitive delay with cerebral malformation such as occipital pachygyria (Tan et al., 2021).
The LAMA2 gene (OMIM 156225), located on chromosome 6q22.33, encodes the laminin α2 chain (also known as merosin) predominantly localized to the basal lamina of myofibers in skeletal muscle, Schwann cells in peripheral nerve, and cerebral blood vessels detected by immunofluorescence and immunoelectron microscopy (Leivo and Engvall, 1988; Villanova et al., 1997; Malandrini et al., 1997). Laminin α2 connects with laminin β1 and γ1 chains to form a heterotrimeric protein laminin-α2β1γ1 (LM-211). LM-211 anchors to two major groups of receptors on the cell surface, α-dystroglycan and integrins (α1β1, α2β1, α6β1, α7β1), to form dystroglycan-matrix scaffolds and regulate signal transductions (Hoheneste, 2019; Durbeej, 2010; Aumailley, 2021). It was reported that the deficiency of laminin α2 in astrocytes and pericytes was associated with a defective blood-brain barrier (BBB) in the dy3K/dy3K mice (Menezes et al., 2014). The defective BBB presented with altered integrity and composition of the endothelial basal lamina, reduced pericyte coverage, and hypertrophic astrocytic endfeet lacking appropriately polarized aquaporin4 channels. It has been suspected that laminin α2 deficiency is responsible for disruption of the basement membrane assembly (Yurchenco et al., 2018), leading to defects in the gliovascular basal lamina of the BBB (Gawlik and Durbeej, 2020; Menezes et al., 2014; Arreguin and Colognato, 2020), and the muscle damages.
Mouse models are the most frequently used to investigate the pathogenic mechanism for muscular dystrophies. The most common mouse models for LAMA2-MD are the dy/dy, dy3k/dy3k, dyw/dyw and dy2J/dy2J mice (Xu et al., 1994; Michelson et al., 1995; Miyagoe et al., 1997; Kuang et al., 1998; Sunada et al., 1995). Among them, the dy/dy, dy3k/dy3k, dyw/dyw mice present severe muscular dystrophy, and dy2J/dy2J mice show mild muscular dystrophy and peripheral neuropathy (Gawlik and Durbeej, 2020). The mutation of the dy/dy mice has been still unclear (Xu et al., 1994; Michelson et al., 1995). The dy3k/dy3k mice were generated by inserting a reverse Neo element in the 3’ end of exon 4 of Lama2 gene in 1997 (Miyagoe et al., 1997), and the dyw/dyw mice were created with an insertion of lacZ-neo in the exon 1 of Lama2 gene in 1998 (Kuang et al., 1998). The dy2J/dy2J mice were generated in 1970 by a spontaneous splice donor site mutation which resulted in a predominant transcript with a 171 base in-frame deletion, leading to the expression of a truncated laminin α2 with a 57 amino acid deletion (residues 34-90) and a substitution of Gln91Glu (Sunada et al., 1995). They were established in the pre-gene therapy era, leaving trace of engineering, such as bacterial elements in the Lama2 gene locus, thus unsuitable for testing various gene therapy strategies. Moreover, insufficient transcriptomic data of the muscle and brain of LAMA2-CMD mouse models limits the understanding of disease hallmarks. Therefore, there is a need to create new appropriate mouse models for LAMA2-CMD based on human high frequently mutated region using the latest gene editing technology such as clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9.
Our previous studies have suggested that exons 3-4 region of the LAMA2 gene is the most frequent mutation region in patients with LAMA2-MD (Tan et al., 2021; Ge et al., 2018). Building on this discovery, we utilized CRISPR-Cas9 gene editing technology to specifically delete the exon 3 of Lama2 gene, creating a novel Lama2 knockout (KO) mouse model for LAMA2-MD, named “dyH/dyH”. Through the analysis of phenotype, the muscle pathology, and the expression of laminin α2 protein, we confirmed that dyH/dyH mice presented a phenotype with severe muscular dystrophy. Then, we conducted single-cell RNA sequencing (scRNA-seq), RNA sequencing, western blot and immunofluorescence in the dyH/dyH mice to investigate the molecular pathogenetic mechanisms of muscular dystrophy and brain dysfunction for LAMA2-CMD.
Results
dyH/dyH mice: A novel mouse model for LAMA2-MD
We have created a new mouse model dyH/dyH for human LAMA2-MD that closely simulates human neuropathology and clinical phenotype (Figure 1). This was generated by targeted deletion of Lama2 gene exon 3 with CRISPR-Cas9 gene editing technology (Barazesh et al., 2021). To assess the phenotype of these Lama2 KO mice, we recorded the general appearance, body weight, life span and motor function of wild-type (WT), heterozygote (Het, dyH/+), and homozygous dyH/dyH mice (Figure 2–figure supplement 1). The dyH/dyH mice were smaller with lower weight when compared with the WT and Het mice (Figure 2–figure supplement 1). They had delayed weight gain when observed at postnatal days 7 (P7) and worsened through P10 to P24 (Figure 2A). Kaplan–Meier survival analysis revealed that the median survival of dyH/dyH mice was 21 days (ranged from 12 to 35 days) (Figure 2A), while WT and Het mice were in good health throughout the observation period of one year. The dyH/dyH mice were more motionless and inactive than the WT and Het mice (Video supplement 1-3). At P7, the dyH/dyH mice experienced challenges in maintaining an upright stance and difficulty righting from supine (Video supplement 1). By P14, these mice were not only less active and smaller than their WT counterparts, but also displayed significant muscle weakness (Video supplement 2). This weakness progressed rapidly, reaching a debilitating state at age of 3 to 4 weeks (Video supplement 3-4). The average four-limb grip strength of the dyH/dyH mice presented slow improvement over the course of 21 days post birth, followed by a subsequent decline. Meanwhile, the four-limb grip strength of the dyH/dyH mice remained consistently lower than that of the WT and Het mice at all time points (P10, P14, P17, P21 and P24) (Figure 2A). During the period from P18 to P24, the dyH/dyH mice demonstrated inferior performance on the treadmill with a significantly higher number of electric shocks compared to their WT counterparts at time points of P18, P19, P21, P22, P23, and P24 (Figure 2A). These observations collectively indicated a severe phenotype in the dyH/dyH mice, characterized by diminished body weight, profound muscle weakness, and a shortened lifespan.
To further investigate the muscle pathology of the dyH/dyH mice, we measured the serum creatine kinase (CK) levels, conducted muscle magnetic resonance imaging (MRI) studies, and performed muscle histopathological analyses.
Serum CK: The mean serum CK levels of the WT, heterozygous (Het) and dyH/dyH mice were 87.68 ± 11.92 ng/mL, 82.80 ± 4.57 ng/mL, and 769.67 ± 395.54 ng/mL at P14, and 77.85 ± 14.95 ng/mL, 69.11 ± 6.42 ng/mL, and 786.29 ± 415.58 ng/mL at P21, respectively. The result showed that the mean serum CK levels were significantly elevated in the dyH/dyH mice when compared to the WT mice at both postnatal days 14 (P14) (p = 0.004) and 21 (P21) (p = 0.009). There was no discernible difference in serum CK levels between the WT and heterozygous (Het) mice (Figure 2A).
Muscle MRI: The mean relative muscle areas on T1W MRI of pelvic and hindlimb muscle MRI of the WT and dyH/dyH mice were 3.58 ± 0.96 and 1.84 ± 0.73 at P14, and 8.52 ± 4.98 and 3.77 ± 0.63 at P21, respectively, indicated the dyH/dyH mice displayed substantially smaller muscle volumes at both P14 (p < 0.001) and P21 (p < 0.001). Additionally, on T2-weighted MRI, the mean relative hyperintense levels of the WT and dyH/dyH mice were 96.17 and 136.85 at P14, and 96.99 and 135.32 at P21, respectively, indicating significantly increased hyperintense in the dyH/dyH muscles at both P14 (p < 0.001) and P21 (p < 0.001) (Figure 2B).
Muscle histopathology: Compared to that of age-matched WT mice, biceps femoris muscle of the dyH/dyH mice revealed increased variation in fiber size at P7, severe dystrophic changes including muscle fiber degeneration, necrosis, and regeneration at P14. There was a significant increase in connective tissue infiltration and inflammation in the dyH/dyH muscles from P7 (Figure 3–figure supplement 2). Similar dystrophic features were observed in other muscles including quadriceps femoris, gastrocnemius, triceps brachii, diaphragm, and tongue (Figure 4A–figure supplement 3). Notably, heart and intestinal muscles were spared from dystrophic changes (Figure 4A–figure supplement 3). Western blot analysis revealed that the 300-kDa laminin α2 protein was absent in the dyH/dyH muscle samples, but it was normally expressed in the WT muscle samples (Figure 4B), strongly indicating a complete loss of laminin α2 protein in the dyH/dyH mice. Immunofluorescence staining further confirmed the deficiency of laminin α2 protein in muscle tissue of the dyH/dyH mice (Figure 4C).
These findings collectively indicated that the phenotype of dyH/dyH mice was the severe muscular dystrophy, and established a novel mouse model for human LAMA2-CMD.
Disruption of blood-brain barrier in dyH/dyH mouse brain
The blood-brain barrier (BBB) is composed of several cell types, including microvascular endothelial cells, pericytes, astrocytes, vascular smooth muscle cells, and the basement membrane (Villanova et al., 1997; Villanova et al., 1996; Hagg et al., 1997). These components along with microglia collectively form the structure known as the neurovascular unit. Previous studies have indicated that laminin α2 is prominently expressed in astrocytes and pericytes, and it is primarily localized to the basal lamina of cerebral blood vessels in the adult human brain (Mohassel et al., 2018; Arreguin et al., 2020).
To study the molecular mechanisms underlying the brain abnormalities in the dyH/dyH mice, we conducted a comprehensive analysis of laminin α2 expression on the brains of the dyH/dyH (KO) and WT mice at P14. Single-cell RNA sequencing (scRNA-seq) was performed to compare the transcriptional profiles between dyH/dyH and WT mice brains. A total of 8,111 cells from the dyH/dyH mouse brain and 8,127 cells from the WT mouse brain were captured using the 10X Genomics platform (Figure supplement 4A, B). The cell clusters within both the dyH/dyH and WT brains were annotated through aggregation of the sequencing data that resulted in the classification of these clusters into three major categories: neuronal cells, glial cells, and non-neuronal cells. Fifteen distinct clusters, identified with marker genes, (Figure supplement 4C, D), included hippocampal neurons (Hippo-neuron), glutamatergic neurons (Glu-neuron), GABAergic neurons (GABA-neuron), neuron-glial antigen 2 neurons (NG2-neuron), neuron-C5, astrocytes (Astro), cerebellum glia cells (CGC), oligodendrocytes (Oligo), microglia (Micro), vascular and leptomeningeal fibroblasts (VLF), vascular smooth muscle cells (VSM), choroid plexus cells (CPC), ependymal cells (Epen), endothelial cells (Endo), and macrophages (Macro) (Figure 5A, B). The comparative analysis of cell clusters between the dyH/dyH and WT brains revealed a notable increase in the proportion of GABAergic neurons (dyH/dyH: 5.3% vs WT: 3.1%) and a decrease in astrocytes (dyH/dyH: 17.1% vs WT: 20.7%) and glutamatergic neurons (dyH/dyH: 10.0% vs WT: 10.5%) in the dyH/dyH brain (Figure 5C).
To ascertain which cell types expressed laminin α2, we conducted RNA sequencing analysis to measure the Lama2 expression within each cell cluster. The findings revealed that in the WT mouse brain, Lama2 exhibited selective and robust expression in vascular and leptomeningeal fibroblasts and vascular smooth muscle cells with a low level of expression in astrocytes (Figure 5D). Of note, Lama2 was predominantly expressed in astrocyte clusters 1 and 2 (Figure supplement 4E). The immunofluorescence analysis found that the laminin α2 was predominantly observed on the cortical surface, and co-localized with glial fibrillary acidic protein (GFAP, a marker of astrocyte) in the WT mice at P14 (Figure 5E). In contrast, laminin α2 protein was absent and the expression of GFAP was reduced in the leptomeningeal of the dyH/dyH mice (Figure 5C, E). The results suggested that laminin α2, the main component of the gliovascular basal lamina, was crucial for the leptomeningeal and astrocytes on the cortical surface.
Differentially expressed genes (DEGs) in each cell cluster between the dyH/dyH and WT brains were analyzed to uncover the aberrant transcriptional patterns across various cell types in the dyH/dyH mouse brain. As anticipated, Lama2 expression was significantly diminished in vascular and leptomeningeal fibroblasts, vascular smooth muscle cells, and astrocytes in the dyH/dyH brain, compared to the WT brain (Figure 5D–figure supplement 4E). Gene Ontology (GO) terms analysis revealed that the DEGs were enriched in several extracellular matrix processes within vascular and leptomeningeal fibroblasts. For vascular smooth muscle cells, the DEGs were associated with the pathway of cytoplasmic side of the membrane, axon and astrocyte projections (Figure 5F). Our findings suggested that the structure and function of the BBB and pia mater were disrupted as a consequence of Lama2 knockout.
To delve into the alterations within the intricate network of the brain, particularly the BBB, cell-cell communications were predicted by CellChat V1.6, a tool which quantitatively inferred and analyzed intercellular communication networks from scRNA-seq data (Jin et al., 2021). Upon a more detailed investigation of communications among different cell populations, it was found that the distribution of communications was largely similar between the dyH/dyH and WT brains. Notably, the most robust communications were observed between vascular and leptomeningeal fibroblasts and astrocytes, and the levels of communications involving vascular and leptomeningeal fibroblasts were high (Figure 5G). Although the overall distribution and strength of communications were not significantly different between the dyH/dyH and WT brains, noticeable differences were observed in the communications associated with the laminins’ pathway. Notably, the pairs of communication pathways involving Lama2 and its receptors (integrins and Dag1) were presented only in the WT brain, whereas the ligand-receptor pairs related to Lama1 were exclusively observed in the dyH/dyH brain. Moreover, several pairs demonstrated higher communication levels in the dyH/dyH brain than in the WT brains (Figure 6A). These findings suggested that the loss of communications associated with laminin α2, which mediates connections between the extracellular matrix and cell membranes, led to the activation of compensatory communications within other laminin pathways, which provided important information for the Lama1 gene replacement therapy. Significant differences in cell-cell communications were particularly evident in pairs involving vascular and leptomeningeal fibroblast-astrocyte, vascular and leptomeningeal fibroblast-vascular smooth muscle cell, vascular and leptomeningeal fibroblast-endothelial cell, and vascular and leptomeningeal fibroblast-cerebellum glia cell pairs (Figure 6A).
We also found that several genes expressed differently across more than 5 cell clusters (Figure 6B–table supplement 1). Notably, the expression levels of myelin-related genes Mbp, Mobp, and Plp1 (Kristiansen et al., 2008) were significantly reduced in multiple cell clusters in the dyH/dyH brain compared to the WT brain, suggesting potential disruptions in the formation or development of the myelin sheath. The altered expression of the myelin-related genes supported important data for the abnormal brain white matter observed in human LAMA2-MD (Tan et al., 2021). Also, there were some genes associated with the transmembrane ionic transportation, regulation of synaptic transmission, and maintenance of BBB homeostasis, showing differential expression across several cell clusters (Figure 6B):
The expression of Slc1a2, associated with the BBB transport, was significantly decreased in GABAergic neurons, vascular smooth muscle cells, and choroid plexus cells in the dyH/dyH brain compared to the WT brain.
The expression of Mt3, involved in transmembrane ionic transportation was significantly decreased in glutamatergic neurons, GABAergic neurons, vascular smooth muscle cells, and macrophages in the dyH/dyH brain compared to the WT brain.
The expression of Slc6a13, involved in synaptic transmission, was notably increased in vascular and leptomeningeal fibroblasts of the dyH/dyH mice.
In conclusion, these scRNA-seq analysis findings indicated that the loss of laminin α2 in vascular and leptomeningeal fibroblasts, vascular smooth muscle cells, and astrocytes might contribute to the disruption of the BBB integrity. These findings also provided preliminary evidence for the dysfunction of glutaminergic- and GABAergic neuronal systems and the disruptions of ionic homeostasis in the dyH/dyH mouse brain caused by the loss of laminin α2.
Impaired muscle cytoskeleton and activated muscle regeneration in dyH/dyH mice
In previous studies of LAMA2-MD (Nguyen et al., 2019; Gawlik and Durbeej, 2020), the focus on the pathogenesis of muscular dystrophy was primarily concentrated on the secondary histopathological changes such as fibrosis, inflammation, apoptosis, and metabolism. However, relatively less attention was paid to the changes of muscle cytoskeleton and muscle development. The muscle cytoskeletons form a complex and interconnected network that is crucial for maintaining both cellular contractility and mechanical stability of the muscle fibers (Henderson et al., 2017). To further study the molecular mechanisms of muscle cytoskeleton and development as well as the secondary changes to underly the muscle pathology, we conducted a bulk-cell RNA sequencing (bcRNA-seq) on biceps femoris muscles obtained from the WT, heterozygote (Het, dyH/+), and dyH/dyH (KO) mice at postnatal day 14 (P14). Principal component analysis (PCA), a technique used to reduce complex data to its principal components for visualization, demonstrated distinct patterns between the dyH/dyH and WT muscle tissues (Figure 7A). A total of 2,020 DEGs were identified, with 1136 genes upregulated and 884 genes downregulated in the KO muscles compared to the WT muscles (Table supplement 2). To pinpoint the biological pathways linked to the pathogenic mechanism in KO muscle tissues, we conducted gene set enrichment analyses (GSEA) using both Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) databases (Huang et al., 2022). The GO function analysis demonstrated that the DEGs were enriched in muscle cytoskeleton, extracellular matrix, and cell membrane. They were particularly notable during muscle development, inflammation, apoptosis, and in the pathways of mitochondrial energy metabolism. To shed light on the previously less understood aspects of dystrophic pathology, we particularly focused on the DEGs related to muscle cytoskeleton and development, which revealed a significant downregulation of several muscle cytoskeleton-related genes in the KO mice. These genes included Myh6, Myh7, Myl3, Myl2, Tuba8, Myoz3, Actc1, Mstn, Tppp, Mylk4, Mybpc2, Mrln, Mybph, Ckmt2, Myct1, and Abra (Figure 7B). The abnormal expressions of muscle cytoskeleton-related proteins including MYHC (myosin heavy chain), MYH2, desmin and β-tubulin, were further assessed by immunofluorescence and Western blot. The immunofluorescence analysis showed a focal and increased expression of MYHC in the dyH/dyH muscles (Figure 8–figure supplement 5A), and the significantly elevated levels of MYHC and MYH2 proteins in the dyH/dyH muscles were detected by Western blot (Figure 8–figure supplement 5B). Desmin and β-tubulin also exhibited focal increases in the dyH/dyH muscles through immunofluorescence analysis, though with no differences by Western blot analysis. These findings provided evidence for the impairment of the muscle cytoskeleton in the KO mice.
Further analysis of DEGs also revealed an upregulation of several myogenic regulatory factors (MRFs) genes, including Myog, Myof, Myo5a, Myh4, Myh3, and Myh8 in the dyH/dyH muscles. Then, we analyzed three known typical MRFs (MYOG, MYOD1 and MYF5) by western blot and immunofluorescence. The western blot analysis showed no significant differences in the total levels of MYOG and MYOD1 proteins in the dyH/dyH muscles (Figure 8–figure supplement 3B). However, the immunofluorescence analysis demonstrated focal increases in the levels of MYOG, MYOD1, and MYF5 proteins in the regions with obvious muscle regeneration in the dyH/dyH muscles (Figure 8–figure supplement 5A). The results indicated the activated muscle regeneration in the KO mice.
Considering that the cell membrane proteins, α-dystroglycan and integrins, are the two major groups of receptors for LM-211, our investigation focused on the hypothesis that genes related to Dag1 and integrins might display differential expression (Hoheneste, 2019; Durbeej, 2010; Aumailley, 2021). Indeed, the integrin-related genes including Itgal, Itgax, Itgam, Itgb2, and Itgb7 were upregulated in the dyH/dyH muscles. Furthermore, protein-protein interaction analysis demonstrated a direct interaction between Lama2 and Itgb2, as well as Lama2 and Itgb7 (Figure 7C). However, in contrast to integrin-related genes, no differential expression of the Dag1 gene was observed, and the α-dystroglycan levels detected by immunofluorescence showed no significant differences (Figure supplement 6). Notably, a series of other cell membrane protein-related DEGs were also identified, further expanding the potential scope of muscle damage mechanisms. These genes included Tmem52, Tmem106a, Tmem176a, Tmem176b, Tmem246, Tmem143, Tmem38a, Tmem233, Tmem177, Tmem25, Tmem37, Tmem86a, Tmem100, Tmem221, Tmem79, and Tmem178 (Table supplement 2). In a word, these findings suggested that the muscle damage in dyH/dyH mice might be potentially mediated by the abnormal integrin signaling and altered transmembrane proteins.
These observations supported important data for the impaired muscle cytoskeleton and abnormal muscle development which were associated with the muscle pathology consequence of severe dystrophic changes in the dyH/dyH mice.
Discussion
Since the initial identification of the merosin-deficient families with LAMA2 homozygous mutations in 1995 (Helbling-Leclerc et al., 1995), LAMA2-CMD has been the most common CMD subtype worldwide (Sframeli et al., 2017; Abdel Aleem et al., 2020; Ge et al., 2019). However, the underlying pathogenesis is still not completely understood and there is no effective treatment. Mouse models are essential tools for studying the pathogenic mechanism and developing therapeutic strategies for human muscular dystrophies and congenital myopathies (Sztretye et al., 2020; van Putten et al., 2020). Here, we generated a LAMA2-CMD mouse model by utilizing a CRISPR/Cas9 technology and based on the frequent disease-causing genetic variants in human patients. We described the close resemblance of the phenotype of the new LAMA2-CMD mouse model to that of the human LAMA2-CMD patients, and we also studied transcriptomic changes to better understand the molecular mechanism.
Recently, cortical malformations including polymicrogyria, lissencephaly-pachygyria, and cobblestone, most severe in the occipital lobe such as occipital pachygyria, have been thought to be an important manifestation of the brain pathology in LAMA2-MD (Jayakody et al., 2020; Camelo et al., 2023). During brain development, laminins are enriched at ventricular and pial surfaces and the BBB to mediate radial glial cells (RGCs) attachment for neuronal migration. The abnormal neuronal migration in specific areas of the cortex due to the lack of RGCs attachment to the gliovascular basal lamina and consequent gaps in that membrane, which was associated with the cortical malformations (Severino et al., 2020). In previous studies, it was reported that laminin α2 deficiency could result in an impaired gliovascular basal lamina of BBB, including altered integrity and composition of the endothelial basal lamina, abnormal pericytes and astrocytic endfeet (Devisme et al., 2012; Menezes et al., 2014). In our studies, the selectively and highly expressed Lama2 gene in vascular and leptomeningeal fibroblasts, and vascular smooth muscle cells, and the predominantly expressed laminin α2 protein on the cortical surface in the WT brain are correspondent to its role in the BBB. The corresponding deficiency of both Lama2 gene and laminin α2 protein in the dyH/dyH brains provided evidence for the impaired gliovascular basal lamina of BBB. Laminins anchor to integrins on the cell surface to form laminins-integrins pathways. As reported, the aberrant BBB function was also associated with the adhesion defect of alpha7 integrin subunit in astrocytes to laminins in the Itga7-/- mice (Chen et al., 2023). In this study, loss of communications involving the laminins’ pathway between laminin α2 and integrins were predicted between vascular and leptomeningeal fibroblasts and astrocytes in the dyH/dyH brain, providing more evidence for the impaired BBB due to laminin α2 deficiency. Thus, the occipital pachygyria in LAMA2-CMD patients might be related to the impaired gliovascular basal lamina of the BBB (Figure 6C).
Seizures have been thought as a main symptom of brain dysfunctions in LAMA2-MD, which might be associated with cortical malformation (Sarkozy et al., 2020; Huang et al., 2023). However, the pathogenesis of seizures in LAMA2-MD remains unclearly known. The occurrence of seizures was thought to be related to the aberrant neuronal network formation and the imbalance of excitability and inhibitory neuronal network and ionic homeostasis (Barkovich et al., 2015; Jayakody et al., 2020). This might be related to the DEGs such as Slc1a2, Mt3, and Slc6a13, which were associated with the glutaminergic- and GABAergic neuronal systems and the ionic homeostasis data.
Compared with other Lama2 deficient mice including dy/dy, dy2J/dy2J, dy3k/dy3k and dyW/dyW, the phenotype of the dyH/dyH mice presented with a very severe muscular dystrophy, which was similar to that of the dy3k/dy3k mice (Table supplement 3). To assess the development of muscular dystrophy from early to late postnatal periods to better understand the pathogenic processes in human LAMA2-CMD, we observed the muscle pathology at different stages. In this study, we observed significant fiber size variations in the muscles of dyH/dyH mice as early as P7. The typical muscle pathological features with marked variation in fiber size, muscle fiber degeneration, necrosis and regeneration accompanying infiltration of inflammatory cells and fibrosis accelerated until P14 and then decelerated until they expired. Muscle inflammation and fibrosis assessed by muscle MRI was previously reported in the dyw/dyw mice at the age of 7 weeks (Vohra et al., 2015). In this study, muscle MRI performed much earlier (age of 2-3 weeks) which provided the changes of muscle pathology at the early stage. We observed a decreased muscle volume due to muscle wasting on T1-weighted MRI and abnormal hyperintense pixels for inflammation on T2-weighted MRI in the dyH/dyH mice. The results were consistent with muscle pathology and indicated that muscle MRI could be a useful method for monitoring changes in muscle pathology of muscular dystrophies in preclinical research (Porcari et al., 2020; Decostre et al., 2013).
Muscle pathological events of limb muscles including triceps brachii, biceps femoris muscle, quadriceps femoris and gastrocnemius from the early postnatal stage to the last stage could provide a better understanding of the changes of muscle damage and pathology with disease progression (Mehuron et al., 2014; Durbeej, 2015; Gawlik et al., 2017). In addition to the limb muscles, the diaphragm and tongue muscles were involved, indicating extensive muscle dystrophic change in the dyH/dyH mice, which was consistent with those previously observed in the dy3k/dy3k mice (Gawlik et al., 2019). The extensive involvement of muscle pathology was associated with low body weight, muscle wasting, and severe generalized weakness which resulted in respiratory failure, feeding difficulty, and the ultimate fatality. These pathological findings and muscle weakness progression in the dyH/dyH mice were closely resembling those seen in human LAMA2-CMD (Zambon et al., 2020; Tan D et al., 2021; Sarkozy et al., 2020; Jain et al., 2019).
Muscle cytoskeleton network is essential for the processes of muscle contraction, force transmission, adaptation of cell shape, cell division and adhesion (Henderson et al., 2017). For example, F-actin and microtubules regulate cellular elasticity and mechanical contraction (Stricker et al., 2010; Hohmann et al., 2019), MYHCs provide chemical energy by hydrolysis of ATP (Lewis et al., 2023), and desmin is associated with the mechanical integrity and mitochondria positioning (Agnetti et al., 2022). Interestingly, we identified a group of differentially expressed genes (DEGs) related to muscle cytoskeleton and development at P14, when the most extensive muscle dystrophic changes were observed in our dyH/dyH mice. It was also reported that muscle cytoskeleton proteins such as myosin-4, titin, actin, myosin-1, myosin-3 and myosin-8 were dysregulated in the dy3k/dy3k mice (de Oliveira et al., 2014). The dysfunction of cytoskeleton network, especially the decreased F-actin, secondary to laminin α2 deficiency would impair the muscle structure and contractile function in dyH/dyH mice, resulting in degeneration and necrosis of muscle fibers (Figure supplement 7).
In addition to the degeneration and necrosis of muscle fibers in the dyH/dyH mice, we also observed active fiber regeneration, which was associated with the abnormal expression of the muscle development-related genes and proteins. In previous reports, muscle development-related genes such as MyoD, Myh3 and Myof5 were upregulated in LAMA2-CMD mouse models (Mehuron et al., 2014; Onofre-Oliveira et al., 2012). Consistent with the previous reports, the proliferation and differentiation-related genes such as Myog, Myof, Myh3 and Myh8 were upregulated in the biceps femoris of the dyH/dyH mice at P14 in our current study. Moreover, MYOG, MYOD1 and MYF5 were increased in discrete areas of the dyH/dyH muscles at P14 (Figure 8A), but the overall levels of MYOG and MYOD1 were decreased by Western blot (Figure 8B). These findings indicated the regeneration of muscle fibers and impaired regeneration occurred simultaneously (Figure supplement 7). However, the mechanisms by which laminin α2 deficiency regulates the expression of these genes and proteins requires further investigation.
Lm-211 connects with several extracellular matrix proteins to form basement membrane and links to the cell membrane, which provides cell microenvironment to maintain the stability of muscle fibers, regulates the transmission of mechanical force, and the development and regeneration of muscle fibers (Zhang et al., 2021). In previous reports, the expression of extracellular matrix proteins such as Col1a1, Col6α2, collagen III, fibronectin, periostin, galectin-1 and biglycan were increased in LAMA2-CMD mouse models (Mehuron et al., 2014; Gawlik et al., 2019; de Oliveira et al., 2014). As expected, in the dyH/dyH mice, following laminin α2 deficiency, extracellular matrix proteins such as collagen VI and laminin α1, and several extracellular matrix proteins-related genes such as Col1a2, Col5a2, Col3a1, Tnc, Fn1 and Ctss were upregulated. This provided evidence compensatory hyperplasia of the extracellular matrix resulted in the pathologic fibrosis. Targeted regulation of specific components of extracellular matrix may provide effective treatment strategies (Ahmad, 2021).
In summary, the present study provided a novel mouse model dyH/dyH for human LAMA2-CMD. This was achieved by targeted deletion of exons 3, a frequent mutation region found in LAMA2-CMD patients. The dyH/dyH mouse presented the phenotype with severe muscular dystrophy. The detailed data involving motor function, muscle and brain pathologies, and transcriptomics changes in the dyH/dyH mice would provide better understanding of the disease process of LAMA2-CMD. This mouse model serves as a valid disease model for further investigation into the underlying pathogenesis of human LAMA2-CMD and developing effective therapeutic strategies.
Materials and methods
Generation of a novel dyH/dyH knockout mouse with ΔExon 3 at Lama2 locus
All studies conducted on the mice were approved by the Animal Ethics Committee of Peking University First Hospital (J202027). All mice were housed and handled according to the guidelines of the Care and Use of Laboratory Animals (NIH Publication, 8th Edition, 2011; http://grants.nih.gov/grants/olaw/Guide-for-the-care-and-use-of-laboratory-animals.pdf). C57BL/6 mice were used and maintained on a congenic background.
To target the exon 3 of the Lama2 gene (gene ID 16773), a pair of sgRNAs (5’-ggctgtgtatcactaattccagg-3′, 5’-atggatcaagatcctatagaagg-3′) targeting intron 2 and intron 3 of the Lama2 gene were designed (Figure 1A). The pCS-4G vectors containing sgRNAs and Cas9 mRNA were coinjected into 270 C57BL/6 zygotes which were subsequently implanted into pseudopregnant mice, and 33 pups were born. Nine (3♀, 6♂) of them were genetically identified as heterozygote with a heterozygous 1,625-base pair (bp) deletion at genomic DNA level, and one was selected as F0 founder which was backcrossed with C57BL/6 mice to produce generation F1 mice. F2 mice generated from the crossed heterozygous F1 mice were genetically identified and used for following studies. The genotypes were identified by two polymerase chain reaction (PCR)-amplifications with primers (Figure 1A–table supplement 4) and PCR products DNA sequencing. The PCR–amplification conditions were as follows: 95 ℃ for 3 min, followed by 30 cycles at 95 ℃ for 15 s, annealing at 62 ℃ for 20 s and elongation at 72 ℃ for 2 min, and a final step at 72 ℃ for 7 min.
The expected sizes observed by 2% agarose electrophoresis analysis were a 1999-bp fragment for the wild-type allele and a 374-bp fragment for the mutant-type allele in the first PCR– amplification, and a 571-bp fragment for the wild-type allele and no fragment for the mutant-type allele in the second PCR-amplification (– Table supplement 4). The F2 mice showing PCR products with a 1999-bp fragment in PCR1 along with a 571-bp fragment in PCR2 were wild-type (WT). Those having a 1999-bp fragment and a 374-bp fragment in PCR1 along with a 571-bp fragment in PCR2 were dyH/+ (Het). Those having a 374-bp fragment in PCR1 along with no fragment in PCR2 were homozygote knockout (KO), dyH/dyH mice (Figure 1B).
Then, genotype identification was further analyzed by reverse transcription (RT)–PCR. Total RNA was isolated from biceps femoris of WT and dyH/dyH, and was reverse transcribed to first strand cDNA using the Reverse Transcription System (A3500, Promega, Madison, Wisconsin, USA). RT–PCR with the forward primer (5’-TGCTTCGAATGCACTCATCACAAC-3′) and the reverse primer (5’- GATATTGTAGAGGGTCAGGCACTCC-3′) was performed to amplify LAMA2 cDNA exons 2-4. The RT–PCR amplification conditions were as follows: 95 ℃ for 5 min, followed by 35 cycles at 95 ℃ for 30 s, annealing at 56 ℃ for 20 s and elongation at 72 ℃ for 50 s, and a final step at 72 ℃ for 5 min. The RT–PCR products were analyzed by DNA sequencing, and the deletion of exon 3, which resulted in a frameshift downstream sequence of Lama2 gene, was confirmed at cDNA level in dyH/dyH mice (Figure 1C).
Single cell RNA sequencing and data process
Two total brains were extracted from 21 days of age dyH/dyH and WT mouse. Single cell RNA-seq libraries were constructed using the Chromium Single Cell 3’ Reagent Kit (10 ⅹ Genomics) according to the manufacturer’s protocol on the brain tissue. Sequencing was performed on Illumina platform. The raw data were processed by CellRanger (https://support.10xgenomics.com/single-cell-gene-expression/software/pipelines/latest/what-is-cell-ranger) to perform sample demultiplexing, barcode processing and single cell 3′ gene counting. The cDNA reads were aligned to the mm10 premRNA reference genome. Only confidently mapped reads with valid barcodes and unique molecular identifiers were used to generate the gene-barcode matrix. Further analyses for quality filtering were performed using the Seurat V4.3 R package. Cells, which have unique feature counts over 3,000 or less than 200 or have > 5% mitochondrial counts, were filtered. After quality filtering and removing unwanted cells from the dataset, we normalized the data by the total expression, multiplied by a scale factor of 10,000 and log-transformed the result, then we performed Cell clustering, gene expression visualization, marker genes identification and differential expression analysis. The threshold for differential expressed genes was set as |log2FoldChange| > 0.5 and p value < 0.05. Then clusterProfiler V4.8 was used for GO and KEGG enrichment of the differentially expressed genes. CellChat V1.6 was used to analyze the cell-cell communications between cell clusters and compared the difference of cell-cell communications between dyH/dyH and WT.
RNA isolation and RNA sequencing
The biceps femoris was obtained from 14-day-old mice of WT (n = 4), Het (n = 6) and dyH/dyH (KO) (n = 6). Total RNA was isolated from the biceps femoris using TRIzol (Invitrogen, Carlsbad, CA). The RNA samples were submitted to CapitalBio (https://www.capitalbiotech.com) for next-generation sequencing with the TruSeq RNA Exome. Paired-end sequencing (2 × 150 bp reads) was performed on successful RNA libraries using the Illumina HiSeq X-Ten platform. During the experiment, investigators were blinded to the samples’ information. The quality of raw reads was first assessed using FastQC. After filtering out low-quality bases and adaptors using FastP, reads were mapped to the mouse genome assembly GRCh38 (Mus_musculus.GRCm38.dna.toplevel.REF.fa) using Hisat2. Samples were subjected to quality control by examining the percentage of reads uniquely mapping to the genome, the percentage of reads mapping to known protein coding sequences, and the number of genes with 90% base coverage. Gene fusions were identified by mapping reads to the mouse genome using StringTie. The additional information about the hidden correlations within obtained dataset was extracted by principal component analysis using dimension reduction which reduces the dimensionality of the original data matrix retaining the maximum amount of variability. Differentially expressed genes (DEGs) were identified by counting the number of reads mapping to each gene from Ensemble 96 (ftp://ftp.ensembl.org/pub/release-96/fasta/mus_musculus/dna/Mus_musculus.GRCm38.dna.toplevel.fa.gz) using featureCounts and StringTie. Transcripts per million (TPM) were analyzed using Stringtie software. The R package DESeq2 was used to detect DEGs and normalize the read count. The Pearson correlation of each sample showed that all samples were highly correlated. The R package clusterProfiler was used for GO function (http://www.geneontology.org/) and GSEA KEGG analysis. Additionally, Gene Set Variation Analysis (GSVA) was employed for GO function and KEGG pathway analysis using the R package GSVA, and the limma package (version 3.25.15; bioinf.wehi.edu.au/limma) was used to detect the differentially enriched functions and pathways (|log2FC|>=1, p-value < 0.05). A clustering dendrogram was used to display the results of dynamic tree cutting and merging.
Muscle pathology, immunofluorescence, and immunohistochemistry
Skeletal muscles (biceps femoris, quadriceps femoris and triceps brachii) were isolated from WT and dyH/dyH mice at P1, P4, P7, P14 and P21. Gastrocnemius muscle, diaphragm, heart, tongue and intestinal muscles were isolated from WT and dyH/dyH mice at P14. Muscle tissues were embedded in optimal cutting temperature compound (Tissue Tek, Torrance, CA) and frozen in liquid nitrogen. Seven μm thick transverse cryosections were stained with hematoxylin and eosin (H&E, Solarbio, Beijing, China), and Sirius Red or subjected to immunostaining. Immunofluorescence was performed according to standard procedures with antibodies against the N-terminus of the laminin α2 chain (rat monoclonal, 4H8-2, Sigma, Saint Louis, USA), the laminin α1 chain (rat monoclonal, MAB4656, R&D Systems, Minneapolis, USA), myogenic differentiation antigen 1 (MYOD1) (mouse monoclonal, ab16148, Abcam, Cambridge, UK), myogenin (MYOG) (mouse monoclonal, MAB66861, R&D Systems, Minneapolis, USA), myogenic factor 5 (MYF5) (mouse monoclonal, MAB4027, R&D Systems, Minneapolis, USA), myosin heavy chain (MYHC) (mouse monoclonal, MAB4470, R&D Systems, Minneapolis, USA), desmin (mouse monoclonal, MA5-15306, invitrogen, CA), CD68 (rabbit IgG, BA3638, Boster, CA), and clone IIH6C4 for α-DG (mouse monoclonal, 05-593, Merck Millipore, Darmstadt, Germany). The secondary antibodies were goat anti-rat IgG 488, goat anti-mouse IgG 488/594, and goat anti-rabbit IgG 488/594 (Abcam, Cambridge, UK).
The slides for H&E, Sirius Red and immunohistochemistry staining were observed by Leica microscopy (DFC295, Wetzlar, Germany) with LAS V4.12, and the slides for immunofluorescence were imaged by a confocal microscope with FV3000 system (Olympus FluoView FV10i, Tokyo, Japan).
Western blot analysis
Total protein was extracted from mouse muscle tissues using RIPA solution (Pplygen, Beijing, China). The protein concentration was determined by a BCA protein assay (Thermo Fisher Scientific Inc., Waltham, MA). Then, denatured proteins were separated by sodium dodecyl sulfate polyacrylamide gels (SDS–PAGE) and transferred to a polyvinylidene fluoride membrane. Electrochemiluminescence was used to observe the bands with an imaging system (molecular imager, ChemiDoc XRS, Bio–Rad, CA). The densities of the bands were determined semiquantitatively by ImageJ software (NIH, Bethesda, MD). Equal protein loading of blots was confirmed by immunoblotting of GAPDH (rabbit monoclonal, #2118, Cell Signaling Technology, Danvers, USA), except β-tubulin (mouse monoclonal, 86298, Cell Signaling Technology, Danvers, USA) used as equal protein for laminin α2. The results were represented as fold of change over the control (wild-type group) value. The antibodies used in this study were as follows: laminin α2 chain (rat monoclonal, 4H8-2, Sigma, Saint Louis, USA), MYOD1 (mouse monoclonal, ab64159, Abcam, Cambridge, UK), MYOG (mouse monoclonal, MAB66861, R&D Systems, Minneapolis, USA), myosin heavy chain 2 (MYH2) (rabbit monoclonal, ab124937, Abcam, Cambridge, UK), MYHC (mouse monoclonal, MAB4470, R&D Systems, Minneapolis, USA), desmin (mouse monoclonal, MA5-15306, Invitrogen, CA), α-actin (rabbit polyclonal, 23660-I-AP, Proteintech, Rosemont, USA), F-actin (rabbit polyclonal, bs-1571R, Bioss, Rosemont, USA). Then, the blots were incubated with horseradish peroxidase-conjugated secondary antibodies (Cell Signaling Technology, Danvers, USA).
Four limbs grip strength test
Muscle strength measurements of the four limbs of mice were performed from P10-P24 using a grip strength meter and SuperGSM software (Shanghai XinRuan Information Technology Co., Ltd.). All four paws of each mouse were allowed to grasp the grid attached to the grip strength meter. After obtaining a good grip, the mouse was pulled away from the grid until the grasp broke. The test was repeated 3 times for each mouse and the mean value was calculated. The results are presented as normalized strength (gram force per gram body weight) (Elbaz et al., 2012). Four-limb grip strength was measured by one person for all trials due to the outcome possibly being highly variable between experimenters.
Treadmill exercise protocol
The mice were forced to run on a motorized treadmill for training prior to the experiment once a day from P13 to P17. The experiment was performed beginning on P18. The dyH/dyH mice that were too fatigued to run were removed from the experiment. The exercise load consisted of 5 min break and interval running cycles for 25 min at a speed of 1 meter/min for 20 s and 2 meters/min for 20 s, with a 0° inclination. Motivation to run was induced by applying 1.0 mA electric foot shocks, one set of electric foot shocks with a 10 s duration. The gait and number of electric shocks were observed.
Determination of the serum CK levels
Approximately 200 μL of blood from each mouse was collected, centrifuged at 4000 rpm for 10 min at 4 °C, and analyzed for CK levels using a mouse CK ELISA Kit (Nanjing Herb-Source Bio-Technology CO., LTD, czy24506). To determine the CK levels, the serum samples were diluted stepwise, 5-, 20-, and 50-fold because the CK level was beyond the linear range, and the CK level was then measured and recorded at the highest dilution.
Muscle MR acquisition
Siemens TIM Trio 3.0 T MRI scanner (Siemens, Erlangen, Germany) was used to detect changes in the muscles. The mice were anesthetized by intraperitoneal injection of 5% chloral hydrate (7 mL/kg), and then placed prostrate on a holder bed with the hip and hindlimbs moved into the center of a small animal-specific coil. High resolution T1-weighted and T2-weighted MRI of the hip and hindlimb muscles were acquired under optimized imaging parameters (Table supplement 5). Relative muscle area (muscle area/fat area) was quantified on T1-weighted MRI, and heterogeneity was quantified in muscles on T2-weighted MRI by averaging the mean intensities in 8-11 regions of interest (ROIs) in 3 slices using ImageJ software (NIH, Bethesda, MD) (Iyer et al., 2020). Images were converted to Digital Imaging and Communication in Medicine (DICOM) format using syngo MR B17 software (Siemens, Erlangen, Germany).
Statistical analysis
An unpaired t-test was used to compare the mean between groups. All graphs related to phenotype analysis were generated using GraphPad Prism 8 software (GraphPad Software, La Jolla, CA). Graphs displayed the mean ± standard deviation (SD). All graphs related to RNA sequencing analysis of mouse muscle tissues were performed using R software version 4.0.4. Statistical analyses were performed using SPSS (version 19.0; IBM-SPSS, Chicago, IL). Two-sided p < 0.05 was considered to be statistically significant.
Acknowledgements
The authors would like to express their gratitude to Dr. Ching H. Wang for his critical reading and editing of this manuscript and Dr. Y. Zhu for his assistance in the analysis of the RNA sequencing data. This study received support from the following grants: National High Level Hospital Clinical Research Funding (High Quality Clinical Research Project of Peking University First Hospital) (No. 2022CR69 to H.X.), National Natural Science Foundation of China (No. 82171393 to H.X.), Natural Science Foundation of Beijing Municipality (No. 7212116 to H.X.), National Key Research and Development Program of China (No. 2016YFC0901505 to H.X.), Beijing Key Laboratory of Molecular Diagnosis and Study on Pediatric Genetic Diseases (No. BZ0317 to H.X.), Research Foundation for Youth Talents of the First Affiliated Hospital of Nanchang University (No. YFYPY202223 to D.T.), and Natural Science Foundation of Beijing Municipality (No. 7242149 to H. L.).
Additional information
Funding
Author contributions
D.T. performed the experiments, analyzed the data, and drafted the manuscript. Y.L. participated in performing the experiments and analyzing the data. H. L. participated in analyzing the single cell sequencing data and contributed to the drafting of the manuscript. Q.S. conducted hematoxylin and eosin (H&E) and Sirius Red staining on mouse muscles. X.L. participated in analyzing the RNA sequencing data and contributed to the drafting of the manuscript. L.X. assisted with the muscle MRI and contributed to the drafting of the manuscript. J.L. performed immunohistochemistry assay on human muscles. H.Z. guided the experiments, analyzed the mouse phenotype data and revised the manuscript. H.X. and N.Z. designed the study, analyzed the data, and contributed to the drafting, reviewing, and finalizing of the manuscript. All authors read and approved the final manuscript.
Competing interests
The patent (202310746431.1) for the method and application of the construction and identification of Lama2 gene knockout mouse model is pending. The authors declare no other competing interests.
Ethics
All procedures were approved by the Animal Ethics Committee of Peking University First Hospital (J202027) and followed the guidelines of the Care and Use of Laboratory Animals.
Data availability
The datasets generated during this study are available from the corresponding authors on reasonable request.
References
- Clinical and genomic characteristics of LAMA2 related congenital muscular dystrophy in a patients’ cohort from Qatar. A population specific founder variantNeuromuscul Disord 30:457–471https://doi.org/10.1016/j.nmd.2020.03.009
- New roles for desmin in the maintenance of muscle homeostasisFEBS J 289:2755–2770https://doi.org/10.1111/febs.15864
- Prospective of extracellular matrix and drug correlations in disease managementAsian J Pharm Sci 16:147–160https://doi.org/10.1016/j.ajps.2020.06.007
- Brain Dysfunction in LAMA2-Related Congenital Muscular Dystrophy: Lessons From Human Case Reports and Mouse ModelsFront Mol Neurosci 13https://doi.org/10.3389/fnmol.2020.00118
- Laminins and interaction partners in the architecture of the basement membrane at the dermal-epidermal junctionExp Dermatol 30:17–24https://doi.org/10.1111/exd.14239
- CRISPR/Cas9 Technology as a Modern Genetic Manipulation Tool for Recapitulating of Neurodegenerative Disorders in Large Animal ModelsCurr Gene Ther 21:130–148https://doi.org/10.2174/1566523220666201214115024
- Malformations of cortical development and epilepsyCold Spring Harb Perspect Med 5https://doi.org/10.1101/cshperspect.a022392
- Brain MRI Abnormalities, Epilepsy and Intellectual Disability in LAMA2 Related Dystrophy - a Genotype/Phenotype CorrelationJ Neuromuscul Dis 10:483–492https://doi.org/10.3233/JND-221638
- The alpha7 integrin subunit in astrocytes promotes endothelial blood-brain barrier integrityDevelopment 150https://doi.org/10.1242/dev.201356
- Cobblestone lissencephaly: neuropathological subtypes and correlations with genes of dystroglycanopathiesBrain 135:469–482https://doi.org/10.1093/brain/awr357
- Longitudinal in vivo muscle function analysis of the DMSXL mouse model of myotonic dystrophy type 1Neuromuscular Disorders 23:1016–1025https://doi.org/10.1016/j.nmd.2013.07.014
- Quantitative proteomic analysis reveals metabolic alterations, calcium dysregulation, and increased expression of extracellular matrix proteins in laminin alpha2 chain-deficient muscleMol Cell Proteomics 13:3001–3013https://doi.org/10.1074/mcp.M113.032276
- Laminin-alpha2 Chain-Deficient Congenital Muscular Dystrophy: Pathophysiology and Development of TreatmentCurr Top Membr 76:31–60https://doi.org/10.1016/bs.ctm.2015.05.002
- LamininsCell Tissue Res 339:259–268https://doi.org/10.1007/s00441-009-0838-2
- Losartan, a therapeutic candidate in congenital muscular dystrophy: Studies in the dy2J/dy2J MouseAnnals of Neurology 71:699–708https://doi.org/10.1002/ana.22694
- Family of Laminin alpha2 Chain-Deficient Mouse Mutants: Advancing the Research on LAMA2-CMDFront Mol Neurosci 13https://doi.org/10.3389/fnmol.2020.00059
- Potent pro-inflammatory and pro-fibrotic molecules, osteopontin and galectin-3, are not major disease modulators of laminin alpha2 chain-deficient muscular dystrophySci Rep 7https://doi.org/10.1038/srep44059
- Early skeletal muscle pathology and disease progress in the dy(3K)/dy(3K) mouse model of congenital muscular dystrophy with laminin alpha2 chain-deficiencySci Rep 9https://doi.org/10.1038/s41598-019-50550-0
- Congenital muscular dystrophies in ChinaClin Genet 96:207–215https://doi.org/10.1111/cge.13560
- Deletion of exon 4 in LAMA2 is the most frequent mutation in Chinese patients with laminin alpha2-related muscular dystrophySci Rep 8https://doi.org/10.1038/s41598-018-33098-3
- Laminins of the adult mammalian CNS; laminin-alpha2 (merosin M-) chain immunoreactivity is associated with neuronal processesBrain Res 764:17–27https://doi.org/10.1016/s0006-8993(97)00419-8
- Mutations in the laminin alpha 2-chain gene (LAMA2) cause merosin-deficient congenital muscular dystrophyNat Genet 11:216–8https://doi.org/10.1038/ng1095-216
- Overview of the Muscle CytoskeletonCompr Physiol 7:891–944https://doi.org/10.1002/cphy.c160033
- Laminin G-like domains: dystroglycan-specific lectinsCurr Opin Struct Biol 56:56–63https://doi.org/10.1016/j.sbi.2018.11.007
- The cytoskeleton-a complex interacting meshworkCells 8https://doi.org/10.3390/cells8040362
- Construction of a Novel Ferroptosis-Related Gene Signature of AtherosclerosisFront Cell Dev Biol 9https://doi.org/10.3389/fcell.2021.800833
- Unique Genotype-Phenotype Correlations within LAMA2-related Limb Girdle Muscular Dystrophy in Chinese PatientsFront Neurol 14https://doi.org/10.3389/fneur.2023.1158094
- Muscle phenotype of a rat model of Duchenne muscular dystrophyMuscle Nerve 62:757–761https://doi.org/10.1002/mus.27061
- Longitudinal changes in clinical outcome measures in COL6-related dystrophies and LAMA2-related dystrophiesNeurology 93:e1932–e1943https://doi.org/10.1212/WNL.0000000000008517
- Inference and analysis of cell-cell communication using CellChatNat Commun 12https://doi.org/10.1038/s41467-021-21246-9
- Cobblestone Malformation in LAMA2 Congenital Muscular Dystrophy (MDC1A)J Neuropathol Exp Neurol 79:998–1010https://doi.org/10.1093/jnen/nlaa062
- Expression of transcripts for myelin related genes in postmortem brain from cocaine abusersNeurochem Res 34:46–54https://doi.org/10.1007/s11064-008-9655-3
- Merosin-deficient congenital muscular dystrophy. Partial genetic correction in two mouse modelsJ Clin Invest 102:844–552https://doi.org/10.1172/JCI3705
- Merosin. a protein specific for basement membranes of Schwann cells, striated muscle, and trophoblast, is expressed late in nerve and muscle developmentProc Natl Acad Sci U S A 85:1544–1548https://doi.org/10.1073/pnas.85.5.1544
- Myosin Heavy Chain as a Novel Key Modulator of Striated Muscle Resting StatePhysiology (Bethesda 38https://doi.org/10.1152/physiol.00018.2022
- Localization of the laminin alpha 2 chain in normal human skeletal muscle and peripheral nerve: an ultrastructural immunolabeling studyActa Neuropathol 93:166–172https://doi.org/10.1007/s004010050598
- Dysregulation of matricellular proteins is an early signature of pathology in laminin-deficient muscular dystrophySkeletal Muscle 4https://doi.org/10.1186/2044-5040-4-14
- The extracellular matrix protein laminin alpha2 regulates the maturation and function of the blood-brain barrierJ Neurosci 34:15260–15280https://doi.org/10.1523/JNEUROSCI.3678-13.2014
- Dystrophia Muscularis: A HEREDITARY PRIMARY MYOPATHY IN THE HOUSE MOUSEProc Natl Acad Sci U S A 41:1079–1084https://doi.org/10.1073/pnas.41.12.1079.1955
- Extracellular matrix-driven congenital muscular dystrophiesMatrix Biol 71:188–204https://doi.org/10.1016/j.matbio.2018.06.005
- Laminin alpha2 chain-null mutant mice by targeted disruption of the Lama2 gene: a new model of merosin (laminin 2)-deficient congenital muscular dystrophyFEBS Lett 415:33–39https://doi.org/10.1016/s0014-5793(97)01007-7
- Current understanding and treatment of cardiac and skeletal muscle pathology in laminin-alpha2 chain-deficient congenital muscular dystrophyAppl Clin Genet 12:113–130https://doi.org/10.2147/TACG.S187481
- Differential expression of genes involved in the degeneration and regeneration pathways in mouse models for muscular dystrophiesNeuromolecular Med 14:74–83https://doi.org/10.1007/s12017-012-8172-3
- Time-dependent diffusion MRI as a probe of microstructural changes in a mouse model of Duchenne muscular dystrophyNmr Biomed 33https://doi.org/10.1002/nbm.4276
- LAMA2-Related Dystrophies: Clinical Phenotypes, Disease Biomarkers, and Clinical Trial ReadinessFront Mol Neurosci 13https://doi.org/10.3389/fnmol.2020.00123
- Definitions and classification of malformations of cortical development: practical guidelinesBrain 143:2874–2894https://doi.org/10.1093/brain/awaa174
- Congenital muscular dystrophies in the UK population: Clinical and molecular spectrum of a large cohort diagnosed over a 12-year periodNeuromuscul Disord 27:793–803https://doi.org/10.1016/j.nmd.2017.06.008
- Mechanics of the F-actin cytoskeletonJ Biomech 43:9–14https://doi.org/10.1016/j.jbiomech.2009.09.003
- Identification of a novel mutant transcript of laminin alpha 2 chain gene responsible for muscular dystrophy and dysmyelination in dy2J miceHum Mol Gene 4:1055–1061https://doi.org/10.1093/hmg/4.6.1055
- From Mice to Humans: An Overview of the Potentials and Limitations of Current Transgenic Mouse Models of Major Muscular Dystrophies and Congenital MyopathiesInt J Mol Sci 21https://doi.org/10.3390/ijms21238935
- Natural history and genetic study of LAMA2- related muscular dystrophy in a large Chinese cohortOrphanet J Rare Dis 16https://doi.org/10.1186/s13023-021-01950-x
- Mouse models for muscular dystrophies: an overviewDis Model Mech 13https://doi.org/10.1242/dmm.043562
- Localization of laminin alpha 2 chain in normal human central nervous system: an immunofluorescence and ultrastructural studyActa Neuropathol 94:567–571https://doi.org/10.1007/s004010050751
- Localization of merosin in the normal human brain: implications for congenital muscular dystrophy with merosin deficiencyJ Submicrosc Cytol Pathol 28:1–4
- Magnetic Resonance Imaging Is Sensitive to Pathological Amelioration in a Model for Laminin-Deficient Congenital Muscular Dystrophy (MDC1A)Plos One 10https://doi.org/10.1371/journal.pone.0138254
- Defective muscle basement membrane and lack of M-laminin in the dystrophic dy/dy mouseProc Natl Acad Sci U S A 91:5572–5576https://doi.org/10.1073/pnas.91.12.5572
- Laminin-deficient muscular dystrophy: Molecular pathogenesis and structural repair strategiesMatrix Biol 71:174–187https://doi.org/10.1016/j.matbio.2017.11.009
- LAMA2-related muscular dystrophy: Natural history of a large pediatric cohortAnn Clin Transl Neurol 7:1870–1882https://doi.org/10.1002/acn3.51172
- Extracellular matrix: an important regulator of cell functions and skeletal muscle developmentCell Biosci 11https://doi.org/10.1186/s13578-021-00579-4
Article and author information
Author information
Version history
- Sent for peer review:
- Preprint posted:
- Reviewed Preprint version 1:
- Reviewed Preprint version 2:
Copyright
© 2024, Tan et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
- views
- 243
- downloads
- 18
- citations
- 0
Views, downloads and citations are aggregated across all versions of this paper published by eLife.